

Microba receives \$2.62 million R&D Tax Incentive Refund

- \$2,626,329 R&D Tax Incentive received for Research & Development Activities conducted during FY22
- The \$2.62m FY22 R&D Tax Incentive combined with Microba's strong financial position (\$26.4m in Cash or equivalents at 30 September 2022) will be utilised to accelerate Microba's therapeutic programs

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that it has received a \$2,626,329 Research & Development Tax Incentive refund relating to R&D activities completed in the 2021/2022 financial year.

The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. The funds received will be reinvested into advancing Microba's three key therapeutic programs in Inflammatory Bowel Disease (IBD), Cancer Immunotherapy and Autoimmune Diseases.

Microba previously announced on 22 July 2022 that it had received two separate Advanced Overseas Findings from AusIndustry, approving eligible overseas expenditure for research and development activities across its Inflammatory Bowel Disease (IBD) and Autoimmune Diseases therapeutic programs. These two Advanced Overseas Findings cover total overseas expenditure of up to \$13,400,000 and may result in R&D Tax Incentive cash rebates to the Company of up to \$5,829,000 across FY22, FY23 and FY24.

Microba's Chief Executive Officer, Dr. Luke Reid, said, "We sincerely appreciate this support from the Australian Government. We believe that Microba's novel therapeutics can make a positive impact on Australian lives in the future, and the R&D Tax Incentive Program is supporting Microba to make this a reality"

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.